Figure 2

Assessment of gliogenic-suppression effect of ruxolitinib in postnatal brain. (A) A schematic diagram depicting the study outline for prenatal transient ruxolitinib treatment. (B) The weight measurement of P1.5 pups (n = 6–21 per group; One-way ANOVA with Dunnett's multiple comparisons) and their brain (n = 4–21 per group; Kruskal–Wallis test with Dunn's multiple comparisons) in vehicle control (G1) and all the treated groups (G2-G6). (C) Immunoblotting analysis for total Jak1 and Jak2, and phosphorylated Jak1 and Jak2 expression in all groups. The corresponding relative pixelation analysis of immunoblotting bands is shown right to the blots (n = 3 per group; unpaired, two-tailed Welsh's t test). (D) Immunoblotting analysis for Tuj1 and Gfap markers in P1.5 whole brains in all groups and the corresponding relative pixelation analysis of immunoblotting bands is shown right to the blots (n = 3 per group; unpaired, two-tailed Welsh's t test). All values represent mean ± SEM; * denotes adjusted p < 0.05; ** denotes adjusted p < 0.01; *** denotes adjusted p < 0.001. See Figs. S1 and S2 for original immunoblots (Supplementary information).